Manufacturing

Aizon secures funds to accelerate development pipeline

Aizon, an artificial intelligence (AI) Software as a Service (SaaS) provider for pharmaceutical manufacturing operations, has secured $20m in Series C funding to expedite its development pipeline.

Kindeva Drug Delivery acquires Summit Biosciences

Kindeva Drug Delivery, a provider of drug-device combination products, has announced the acquisition of Summit Biosciences, an intranasal drug-delivery contract development and manufacturing organisation (CDMO).

Eurofins Alphora completes Canadian biologics development facility

Eurofins CDMO Alphora has announced the completion of a new pilot-scale biologics development facility in Canada.

AGC Biologics to build new facility in Japan

AGC Biologics has announced the establishment of a new manufacturing site at the AGC Yokohama Technical Center in Japan.

Lavipharm signs agreement with Sanofi to acquire Flagyl

Lavipharm has signed an agreement with Sanofi to acquire the pharmaceutical product, Flagyl, for the Greek market, for an undisclosed sum.

Otsuka Pharmaceutical submits NDA for voclosporin in Japan

Aurinia Pharmaceuticals’ collaboration partner Otsuka Pharmaceutical has submitted a new drug application (NDA) to the Japanese Ministry of Health, Labour and Welfare for voclosporin to treat lupus nephritis (LN).

BridgeBio and Resilience partner to develop gene therapies

BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.

STADA to acquire Sanofi’s consumer healthcare brands

German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio.

Danaher to acquire Aldevron from EQT for $9.6bn

Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.